Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics.
Recent evidence suggests that pancreatic cancer and other solid tumors contain a subset of tumorigenic cells capable of extensive self-renewal that contribute to metastasis and treatment resistance. Sorafenib (SO) is a promising new multikinase inhibitor for treatment of advanced kidney and liver cancers. We report here targeting of pancreatic cancer stem cells (CSC) by SO and the development of a strategy to enhance this effect. Although SO administration diminished clonogenicity, spheroid formation, aldehyde dehydrogenase 1 (ALDH1) activity, growth on immunodeficient mice, proliferation, and angiogenesis and induced apoptosis, we observed SO-induced activation of NF-kappaB associated with survival and regrowth of spheroids. For enhanced elimination of CSC characteristics by SO, we cotreated cells with sulforaphane (SF). This broccoli isothiocyanate was recently described to eliminate pancreatic CSCs by downregulation of NF-kappaB activity without inducing toxic side effects. On combination treatment, SF completely eradicated SO-induced NF-kappaB binding, which was associated with abrogated clonogenicity, spheroid formation, ALDH1 activity, migratory capacity, and induction of apoptosis. In vivo, combination therapy reduced the tumor size in a synergistic manner. This was due to induction of apoptosis, inhibition of proliferation and angiogenesis, and downregulation of SO-induced expression of proteins involved in epithelial-mesenchymal transition. Our data suggest that SF may be suited to increase targeting of CSCs by SO.
Rausch
Vanessa
V
Molecular OncoSurgery, University of Heidelberg and German Cancer Research Center, Heidelberg, Germany.
Liu
Li
L
Kallifatidis
Georgios
G
Baumann
Bernd
B
Mattern
Jürgen
J
Gladkich
Jury
J
Wirth
Thomas
T
Schemmer
Peter
P
Büchler
Markus W
MW
Zöller
Margot
M
Salnikov
Alexei V
AV
Herr
Ingrid
I
D000444:Aldehyde Dehydrogenase / Q000378:metabolism; D000080924:Aldehyde Dehydrogenase 1 Family; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001557:Benzenesulfonates / Q000008:administration & dosage; D015153:Blotting, Western; D049109:Cell Proliferation; D002478:Cells, Cultured; D003114:Colony-Forming Units Assay; D004357:Drug Synergism; D024202:Electrophoretic Mobility Shift Assay; D005260:Female; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D015151:Immunoblotting; D007124:Immunoenzyme Techniques; D007527:Isoenzymes / Q000378:metabolism; D017879:Isothiocyanates; D008156:Luciferases / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000473:pathology*; D009389:Neovascularization, Pathologic; D009536:Niacinamide / Q000031:analogs & derivatives; D010190:Pancreatic Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D050697:Retinal Dehydrogenase; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012867:Skin / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D000077157:Sorafenib; D018874:Spheroids, Cellular / Q000378:metabolism; D013454:Sulfoxides; D013861:Thiocyanates / Q000008:administration & dosage; D023041:Xenograft Model Antitumor Assays
D001557:Benzenesulfonates; D007527:Isoenzymes; D017879:Isothiocyanates; D016328:NF-kappa B; D010671:Phenylurea Compounds; D011725:Pyridines; D012333:RNA, Messenger; D013454:Sulfoxides; D013861:Thiocyanates; D009536:Niacinamide; D000077157:Sorafenib; D008156:Luciferases; D000080924:Aldehyde Dehydrogenase 1 Family; D000444:Aldehyde Dehydrogenase; C510223:ALDH1A1 protein, human; C515028:ALDH1A1 protein, mouse; D050697:Retinal Dehydrogenase; C016766:sulforaphane